Your browser doesn't support javascript.
loading
A Randomized, Placebo-Controlled Trial to Assess the Effects of 8 Weeks of Administration of GSK256073, a Selective GPR109A Agonist, on High-Density Lipoprotein Cholesterol in Subjects With Dyslipidemia.
Olson, Eric J; Mahar, Kelly M; Haws, Thomas F; Fossler, Michael J; Gao, Feng; de Gouville, Anne-Charlotte; Sprecher, Dennis L; Lepore, John J.
Affiliation
  • Olson EJ; Clinical Pharmacology and Experimental Medicine, GlaxoSmithKline, Collegeville, PA, USA.
  • Mahar KM; Clinical Pharmacology, Modeling and Simulation, GlaxoSmithKline, Collegeville, PA, USA.
  • Haws TF; Clinical Pharmacology and Experimental Medicine, GlaxoSmithKline, Collegeville, PA, USA.
  • Fossler MJ; Clinical Pharmacology, Modeling and Simulation, GlaxoSmithKline, Collegeville, PA, USA.
  • Gao F; Clinical Statistics, Metabolic Pathways and Cardiovascular Unit, GlaxoSmithKline, Collegeville, PA, USA.
  • de Gouville AC; GlaxoSmithKline Laboratories, Centre de Recherche François Hyafil, Les Ulis Cedex, France.
  • Sprecher DL; Clinical Pharmacology and Experimental Medicine, GlaxoSmithKline, Collegeville, PA, USA.
  • Lepore JJ; Clinical Pharmacology and Experimental Medicine, GlaxoSmithKline, Collegeville, PA, USA.
Clin Pharmacol Drug Dev ; 8(7): 871-883, 2019 10.
Article in En | MEDLINE | ID: mdl-31268250

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Xanthines / Dyslipidemias / Flushing / Cholesterol, HDL Type of study: Clinical_trials Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Pharmacol Drug Dev Year: 2019 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Xanthines / Dyslipidemias / Flushing / Cholesterol, HDL Type of study: Clinical_trials Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Pharmacol Drug Dev Year: 2019 Document type: Article